(Q37478985)

20 August 2017

1 reference

title

Immunoregulatory role of TNFalpha in inflammatory kidney diseases (English)

1 reference

20 August 2017

0 references

Thomas Ernandez

1

1 reference

20 August 2017

Tanya N Mayadas

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

13 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

76

1 reference

20 August 2017

3

1 reference

20 August 2017

262-276

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2009.142

20 August 2017

0 references

cites work

The pathophysiology of tumor necrosis factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Biological functions of tumor necrosis factor cytokines and their receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor (TNF).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor inhibitors for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Drug-induced systemic lupus erythematosus associated with etanercept therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Biphasic effect of interferon-gamma in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The role of tumor necrosis factor-alpha in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Structural features and biochemical properties of TNF-alpha converting enzyme (TACE).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

In situ upregulation of IL-10 reflects the activity of human glomerulonephritides.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Differential cellular immunolocalization of renal tumour necrosis factor-alpha production during ischaemia versus endotoxaemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Unilateral ureteral obstruction induces renal tubular cell production of tumor necrosis factor-alpha independent of inflammatory cell infiltration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cellular localization of inflammatory cytokines in human glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNF ligands and receptors--a matter of life and death

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Genomic organization and promoter function of the murine tumor necrosis factor receptor beta gene

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Two tumour necrosis factor receptors: structure and function.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNF pathophysiology in murine models of chronic inflammation and autoimmunity.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A polymorphism in the 3' untranslated region of the gene for tumor necrosis factor receptor 2 modulates reporter gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNFRSF1A mutations and autoinflammatory syndromes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A novel domain within the 55 kd TNF receptor signals cell death

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The resistance against Listeria monocytogenes and the formation of germinal centers depend on a functional death domain of the 55 kDa tumor necrosis factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The death domain kinase RIP mediates the TNF-induced NF-kappaB signal

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Distinct differences between TNF receptor 1- and TNF receptor 2-mediated activation of NFkappaB.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Induction of apoptosis by TNF receptor 2 in a T-cell hybridoma is FADD dependent and blocked by caspase-8 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cytokine modulation in sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Endothelial activation: intracellular signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cytokines and endothelial cell biology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Chronic Inflammation and Protection from Acute Hepatitis in Transgenic Mice Expressing TNF in Endothelial Cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Activation of mesangial cells with TNF-alpha stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tissue factor production by cultured rat mesangial cells. Stimulation by TNFα and lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Resident kidney cells and their involvement in glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNF-alpha regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune re

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Signaling by the TNF receptor superfamily and T cell homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Induction of apoptosis in mature T cells by tumour necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The death domain kinase RIP protects thymocytes from tumor necrosis factor receptor type 2-induced cell death

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Regulated commitment of TNF receptor signaling: a molecular switch for death or activation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytesin vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Immunological tolerance to a pancreatic antigen as a result of local expression of TNFalpha by islet beta cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

SAP-less chromatin triggers systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Urinary tumor necrosis factor levels in primary glomerulopathies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Failure to induce anti-glomerular basement membrane glomerulonephritis in TNF alpha/beta deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Role of complement and complement regulatory proteins in glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Analysis of the association of HLA-DRB1, TNFalpha promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

New single nucleotide polymorphisms in the coding region of human TNFR2: association with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Haplotype analysis of tumour necrosis factor receptor genes in 1p36: no evidence for association with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Renal expression of IL-6 and TNFalpha genes in lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor in the serum of patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: relevance to the pathogenesis of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase--antineutrophil cytoplasmic autoantibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Chronic rejection: insights from a novel immunosuppressive-free model of kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Role of Cold Ischemia in Acute Rejection: Characterization of a Humoral-Like Acute Rejection in Experimental Renal Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cytokines and chemokine gene expression in human kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Differential expression of cytokines, growth factors, and alpha-smooth muscle actin in renal allograft biopsies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Plasma levels of tumor necrosis factor (TNF) and soluble TNF receptors in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

sTNFRI and sTNFRII synthesis by fine-needle aspiration biopsy sample cultures is significantly associated with acute rejection in kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumour necrosis factor levels during acute rejection and acute tubular necrosis in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Quantitative gene expression of TGF-beta1, TNF-alpha, IL-1beta, and IL-6 in the renal artery wall of chronically rejected human renal allografts.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor receptor -1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The Relative Importance of Cytokine Gene Polymorphisms in the Development of Early and Late Acute Rejection and Six-Month Renal Allograft Pathology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumour necrosis factor-alpha gene polymorphism: implications in kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cytokine gene polymorphisms predict acute graft rejection following renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

IL-2 and TNF-α Promoter Polymorphisms in Patients With Acute Kidney Graft Rejection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

TNF-alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: effects on renal allograft outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Impaired kidney graft survival is associated with the TNF-alpha genotype

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Immune response gene polymorphisms in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cytokine gene polymorphism in kidney transplantation--impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

The cytokine gene polymorphisms in patients with chronic kidney graft rejection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Analysis of cytokine gene polymorphisms in recipient's matched with living donors on acute rejection after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Differentiating the efficacy of the tumor necrosis factor inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

New indications for treatment of chronic inflammation by TNF-alpha blockade

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.142

7 January 2021

Identifiers

DOI

10.1038/KI.2009.142

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference